ORBi: Detailled Reference

Article (Scientific journals)

Fibromyalgie, où en est-on en 2023 ?

Gos, Laura; Staquet, Cécile; LIBBRECHT, Dominique et al.

2023 • In Revue Médicale de Liège, 79 (5), p. 305-14

Peer reviewed

Permalink
https://hdl.handle.net/2268/310001

PubMed
37350207

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

L-Gos_2023_78_5-6_0.pdf

Author postprint (1.02 MB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Fibromyalgie, douleur chronique, syndrome musculo-squelettique

Abstract :

[fr] La fibromyalgie reste une entité clinique nébu leuse dans l’esprit de nombreux praticiens. En effet, cette pathologie associe douleurs chroniques diffuses à une multitude de symptômes tels que des troubles du sommeil, des troubles cognitifs, ainsi que de nombreuses plaintes somatiques variables d’un patient à l’autre. La difficulté réside également dans l’établissement du diagnostic. Celui-ci reste avant tout clinique, en l’absence de lésions anatomiques, d’anomalies biologiques ou anatomo-pathologiques. Les patients passent, généralement, par une phase plus ou moins longue d’errance thérapeutique avant d’avoir une reconnaissance de leur pathologie. La prise en charge doit être multimodale, incluant une revalidation en kinésithérapie, une thérapie cognitivo-comportementale, et un accompagnement médical adapté au cas par cas.

Disciplines :

Anesthesia & intensive care

Author, co-author :

Gos, Laura ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anesthésie - réanimation

Staquet, Cécile ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anesthésie - réanimation

LIBBRECHT, Dominique ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anesthésie - réanimation

Bonhomme, Vincent ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anesthésie - réanimation

Language :

French

Title :

Fibromyalgie, où en est-on en 2023 ?

Alternative titles :

[en] Fibromyalgia, where are we in 2023 ?

Publication date :

2023

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

79

Issue :

5

Pages :

305-14

Peer reviewed :

Peer reviewed

Available on ORBi :

since 17 December 2023

Statistics

Number of views

196 (0 by ULiège)

Number of downloads

505 (2 by ULiège)

More statistics

Scopus citations^®

0

Scopus citations^®
without self-citations

0

OpenAlex citations

0

Bibliography

Treede RD, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain 2019;160:19-27.
Raja SN, Carr DB, Cohen M, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain 2020;161:1976 82.
Roizenblatt S, Neto NS, Tufik S. Sleep disorders and fibromyalgia. Curr Pain Headache Rep 2011;15:347-57.
Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014;311:1547-55.
Backonja MM, Attal N, Baron R, et al. Value of quantitative sensory testing in neurological and pain disorders: NeuPSIG consensus. Pain 2013;154:1807-19.
Carli G, Suman AL, Biasi G, Marcolongo R. Reactivity to superficial and deep stimuli in patients with chronic musculoskeletal pain. Pain 2002;100:259-69.
Petzke F, Clauw DJ, Ambrose K, et al. Increased pain sensitivity in fibromyalgia: effects of stimulus type and mode of presentation. Pain 2003;105:403-13.
Sörensen J, Graven-Nielsen T, Henriksson KG, et al. Hyperexcitability in fibromyalgia. J Rheumatol 1998;25:152-5.
Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain 1997;70:41 51.
Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 1996;68:375-83.
Kosek E, Ekholm J, Hansson P. Increased pressure pain sensibility in fibromyalgia patients is located deep to the skin but not restricted to muscle tissue. Pain 1995;63:335-9.
Sandrini G, Serrao M, Rossi P, et al. The lower limb flexion reflex in humans. Prog Neurobiol 2005;77:353-95.
Truini A, Gerardi MC, di Stefano G, et al. Hyperexcitability in pain matrices in patients with fibromyalgia. Clin Exp Rheumatol 2015;33(Suppl 1):S68-72.
de Tommaso M, Nolano M, Iannone F, et al. Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features. J Neurol 2014;261:461-72.
Lorenz J, Grasedyck K, Bromm B. Middle and long latency somatosensory evoked potentials after painful laser stimulation in patients with fibromyalgia syndrome. Electroencephalogr Clin Neurophysiol 1996;100:165-8.
Lorenz J. Hyperalgesia or hypervigilance? An evoked potential approach to the study of fibromyalgia syndrome. Z Rheumatol 1998;57(Suppl 2):19-22.
O’Brien AT, Deitos A, Triñanes Pego Y, et al. Defective endogenous pain modulation in fibromyalgia: a meta-analysis of temporal summation and conditioned pain modulation paradigms. J Pain 2018;19:819-36.
Hilgenberg-Sydney PB, Kowacs PA, Conti PC. Somatosensory evaluation in dysfunctional syndrome patients. J Oral Rehabil 2016;43:89-95.
Potvin S, Marchand S. Pain facilitation and pain inhibition during conditioned pain modulation in fibromyalgia and in healthy controls. Pain 2016;157:1704-10.
Staud R. Abnormal endogenous pain modulation is a shared characteristic of many chronic pain conditions. Expert Rev Neurother 2012;12:577-85.
Lautenbacher S, Rollman GB, McCain GA. Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. Pain 1994;59:45-53.
Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 1996;68:375-83.
Hilgenberg-Sydney PB, Kowacs PA, Conti PC. Somatosensory evaluation in dysfunctional syndrome patients. J Oral Rehabil 2016;43:89-95.
Price DD, Staud R, Robinson ME, et al. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 2002;99:49-59.
Tak LM, Cleare AJ, Ormel J,, et al. Meta-analysis and meta-regression of hypothalamic-pituitary-adrenal axis activity in functional somatic disorders. Biol Psychol 2011;87:183-94.
Martínez-Martínez LA, Mora T, Vargas A, et al. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis. J Clin Rheumatol 2014;20:146-50.
Martinez-Lavin M. Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia. Arthritis Res Ther 2007;9:216.
Gerdle B, Ernberg M, Mannerkorpi K, et al. Increased interstitial concentrations of glutamate and pyruvate in vastus lateralis of women with fibromyalgia syndrome are normalized after an exercise intervention – a case-control study. PLoS One 2016;11:e0162010.
Lawson VH, Grewal J, Hackshaw KV, et al. Fibromyalgia syndrome and small fiber, early or mild sensory polyneuropathy. Muscle Nerve 2018;58:625-30.
Serra J, Collado A, Solà R, et al. Hyperexcitable C nociceptors in fibromyalgia. Ann Neurol 2014;75:196-208.
Üçeyler N, Häuser W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 2011;12:245.
Cedraschi C, Girard E, Luthy C, et al. Primary attributions in women suffering fibromyalgia emphasize the perception of a disruptive onset for a long-lasting pain problem. J Psychosom Res 2013;74:265-9.
Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319-29.
Perrot S, Bouhassira D, Fermanian J. Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Pain 2010;150:250-6.
Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28.
Heidari F, Afshari M, Moosazadeh M. Prevalence of fibromyalgia in general population and patients, a systematic review and meta-analysis. Rheumatol Int 2017;37:1527-39.
Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 2006;12:124-8.
Don L Goldenberg M. Differential diagnosis of fibromyalgia. Am J Med 2009;122(Suppl12):S14-221.
Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. 2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag 2013;18:119-26.
Kengen Traska T, Rutledge DN, Mouttapa M, et al. Strategies used for managing symptoms by women with fibromyalgia. J Clin Nurs 2012;21:626-35.
Durif-Bruckert C, Roux P, Rousset H. Medication and the patient-doctor relationship: a qualitative study with patients suffering from fibromyalgia. Health Expect 2015;18:2584-94.
Ranque B, Nardon O. Prise en charge des symptômes médicalement inexpliqués en médecine interne: un paradigme de la relation médecin-malade en situation d’incertitude. Rev Med Interne 2017;38:458-66.
Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis 2017;76:318-28.
Amutio A, Franco C, Sánchez-Sánchez LC, et al. Effects of mindfulness training on sleep problems in patients with fibromyalgia. Front Psychol 2018;9:1365.
Brooks JM, Muller V, Sánchez J, et al. Mindfulness as a protective factor against depressive symptoms in people with fibromyalgia. J Ment Health 2020;29:161-7.
Welsch P, Üçeyler N, Klose P, et al. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev 2018;2:CD00292.
Derry S, Cording M, Wiffen PJ, et al. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev 2016;9:CD011790.
Cooper TE, Derry S, Wiffen PJ, Moore RA. Gabapentin for fibromyalgia pain in adults. Cochrane Database Syst Rev 2017;1:CD012188.
Avorn J. Drug Warnings That can cause fits: communicating risks in a data-poor environment. N England J Med 2008;359:991-4.
Agence Fédérale des Médicaments et des Produits de Santé. Flash VIG-news: Prégabaline (Lyrica et génériques): risques de mésusage, d’abus et de dépendance. Disponible sur: https://www.afmps.be/fr/news/flash_vig_news_pregabaline_lyrica_et_generiques_risques_de_mesusage_dabus_et_de_dependance.2022.
Häuser W, Sarzi-Puttini P, Tölle TR, Wolfe F. Placebo and nocebo responses in randomised controlled trials of drugs applying for approval for fibromyalgia syndrome treatment: systematic review and meta-analysis. Clin Exp Rheumatol 2012;30(6 Suppl 74):78-87.
Moore RA, Derry S, Aldington D, et al. Amitriptyline for fibromyalgia in adults. Cochrane Database Syst Rev 2019:5:CD011824.
Cruccu G, Garcia-Larrea L, Hansson P, et al. EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol 2016;23:1489-99.
O’Connell NE, Marston L, Spencer S, et al. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database Syst Rev 2018;4:CD008208.
de Araújo TA, Mota MC, Crispim CA. Obesity and sleepiness in women with fibromyalgia. Rheumatol Int 2015;35:281-7.
Cullen KL, Irvin E, Collie A, et al. Effectiveness of workplace interventions in return-to-work for musculoskeletal, pain-related and mental health conditions: an update of the evidence and messages for practitioners. J Occup Rehabil 2018;28:1-15.
Löfgren M, Ekholm J, Öhman A. ‘A constant struggle’: Successful strategies of women in work despite fibromyalgia. Disabil Rehabil 2006;28:447-55.
Palstam A, Larsson A, Bjersing J, et al. Perceived exertion at work in women with fibromyalgia: Explanatory factors and comparison with healthy women. J Rehabil Med 2014;46:773-80.

Similar publications